The results showed that target gene silencing rate is very high, up to about 60% at one day and about 80% at two days after treatment (Fig. 7A), providing an in vivo methodology for OBP gene silencing in BPH. The gene discussed is KIF22; the disease is benign prostatic hyperplasia.